for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dare Bioscience Inc

DARE.O

Latest Trade

1.28USD

Change

0.00(0.00%)

Volume

783,684

Today's Range

1.23

 - 

1.44

52 Week Range

0.69

 - 

3.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Daré Bioscience Begins Trial For Contraceptive Candidate Ovaprene

* DARÉ BIOSCIENCE, INC. ANNOUNCES TRIAL INITIATION FOR OVAPRENE® NON-HORMONAL MONTHLY CONTRACEPTIVE CANDIDATE

BRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer

* DARÉ BIOSCIENCE, INC. EXPANDS LEADERSHIP TEAM, APPOINTING JOHN FAIR TO CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients

* DARÉ BIOSCIENCE, INC. ENTERS INTO AGREEMENT TO ACQUIRE PRODUCT TO ADDRESS VULVAR AND VAGINAL ATROPHY IN HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

BRIEF-Dare Bioscience Says Board Increased Size To 6 Directors

* DARE BIOSCIENCE - ON APRIL 9, BOARD INCREASED SIZE OF BOARD FROM 5 DIRECTORS TO 6 DIRECTORS , ELECTED JESSICA GROSSMAN TO FILL VACANCY - SEC FILING Source: (https://bit.ly/2v7rEnA) Further company coverage:

BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil

* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Dare Bioscience Announces Development And Option Agreement With Orbis Biosciences For Long-Acting Injectable Contraceptive

* DARÉ BIOSCIENCE ANNOUNCES EXCLUSIVE DEVELOPMENT AND OPTION AGREEMENT WITH ORBIS BIOSCIENCES FOR LONG-ACTING INJECTABLE CONTRACEPTIVE

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING Source text - (http://bit.ly/2CC1wzx) Further company coverage:

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln

* DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION

BRIEF-Daré Bioscience Announces Proposed Public Offering Of Common Stock

* DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies

* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES

BRIEF-Dare Bioscience Says Entered Into Common Stock Sales Agreement

* DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING

BRIEF-Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial

* Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up